BioVaxys Technology Corp.
BIOV
CNSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 83.37% | 123.64% | 86.74% | 36.31% | 11.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.06% | 125.16% | 87.03% | 28.75% | -1.44% |
| Operating Income | -87.06% | -125.16% | -87.03% | -28.75% | 1.44% |
| Income Before Tax | -63.44% | -16.41% | 12.67% | 49.32% | 74.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.44% | -16.41% | 12.67% | 49.32% | 74.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.44% | -16.41% | 12.67% | 49.32% | 74.27% |
| EBIT | -87.06% | -125.16% | -87.03% | -28.75% | 1.44% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -7.49% | 29.47% | 47.58% | 72.15% | 82.75% |
| Normalized Basic EPS | -14.29% | 50.34% | 57.92% | 67.54% | 67.76% |
| EPS Diluted | -7.49% | 29.47% | 47.58% | 72.15% | 82.75% |
| Normalized Diluted EPS | -14.29% | 50.34% | 57.92% | 67.54% | 67.76% |
| Average Basic Shares Outstanding | 50.88% | 56.94% | 64.34% | 52.10% | 44.57% |
| Average Diluted Shares Outstanding | 50.88% | 56.94% | 64.34% | 52.10% | 44.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |